HPV vaccine stops cervical intraepithelial neoplasiaBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.335.7609.16-b (Published 05 July 2007) Cite this as: BMJ 2007;335:16
Human papillomavirus (HPV) types 16 and 18 cause about 70% of cervical cancer worldwide. At least one vaccine is already available, and others are in development, including a bivalent vaccine against HPV types 16 and 18 developed by GlaxoSmithKline. The vaccine, which is a …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial